Dian He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dian He has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Xiaoyang Lei
Department of Neurology, Guizhou Provincial People’s Hospital, Guiyang, China
19 shared publicationsChao Tang
Department of Neurology, Guizhou Provincial People’s Hospital, Guiyang, China
15 shared publicationsJiaxin Yang
Department of Neurology, Guizhou Provincial People’s Hospital, Guiyang, China
8 shared publicationsMing Zhang
Department of Neurology, Guizhou Provincial People’s Hospital, Guiyang, China
8 shared publicationsXiaoxue Peng
Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, China
8 shared publicationsSushuang Yang
Department of Neurology, Affiliated Hospital of Guizhou Medical University, Yunyan District, Guiyang, China
7 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1953059
Case Report: Unplanned pregnancy during treatment with inebilizumab in patients with AQP4-IgG-seropositive NMOSD: report of two cases
Neuromyelitis optica spectrum disorder (NMOSD) predominantly affects women and has a median age at onset of 40 years, meaning that many patients are of childbearing age. However, management of pregnant women with NMOSD remains extremely challenging. We report two patients with NMOSD who had unplanned pregnancies during inebilizumab (INE) treatment and successful deliveries. These cases provide preliminary clinical information regarding maternal disease control and pregnancy outcomes following INE exposure.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1953059
Open AccessCase Report: Unplanned pregnancy during treatment with inebilizumab in patients with AQP4-IgG-seropositive NMOSD: report of two cases
Neuromyelitis optica spectrum disorder (NMOSD) predominantly affects women and has a median age at onset of 40 years, meaning that many patients are of childbearing age. However, management of pregnant women with NMOSD remains extremely challenging. We report two patients with NMOSD who had unplanned pregnancies during inebilizumab (INE) treatment and successful deliveries. These cases provide preliminary clinical information regarding maternal disease control and pregnancy outcomes following INE exposure.
- Open Access
- 16 September 2026
- Published by Springer Nature in npj Parkinson's Disease
Beyond motor symptoms: associations between sleep disorders and multidomain functional decline in Parkinson’s disease
- 16 September 2026
- Published by Springer Nature in npj Parkinson's Disease
Open AccessBeyond motor symptoms: associations between sleep disorders and multidomain functional decline in Parkinson’s disease
- 22 July 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (4) , 115
Comprehensive Characterization of Clinical Phenotypes and CTG Repeat-Associated Manifestations in Spinocerebellar Ataxia Type 8
- 22 July 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (4) , 115
Comprehensive Characterization of Clinical Phenotypes and CTG Repeat-Associated Manifestations in Spinocerebellar Ataxia Type 8
- 20 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218350
Rapidly Progressive Alzheimer Disease and Related Dementias as a Phase Transition
Background and ObjectivesRapidly progressive Alzheimer disease and related dementias (rpADRD) is a clinically urgent syndrome characterized by accelerated deterioration. Because it is often confoun...
- 20 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (3) , e218350
Rapidly Progressive Alzheimer Disease and Related Dementias as a Phase Transition
Background and ObjectivesRapidly progressive Alzheimer disease and related dementias (rpADRD) is a clinically urgent syndrome characterized by accelerated deterioration. Because it is often confoun...
- 1 June 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 149, 108371
Compound heterozygous PINK1 variants including a novel frameshift in a Chinese family with Parkinson's disease
- 1 June 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 149, 108371
Compound heterozygous PINK1 variants including a novel frameshift in a Chinese family with Parkinson's disease
- Open Access
- 3 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71439
Reply to: Beyond AUC: Advancing clinical interpretability of depression–MRI–machine learning analyses in Alzheimer's disease
- 3 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71439
Open AccessReply to: Beyond AUC: Advancing clinical interpretability of depression–MRI–machine learning analyses in Alzheimer's disease
- Open Access
- 16 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100568
The concurrent burden of Alzheimer’s pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline
- 16 April 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (6) , 100568
Open AccessThe concurrent burden of Alzheimer’s pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline
- Open Access
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1767562
Identification of key genes and metabolites in acute ischemic stroke via integrated transcriptomic and metabolomic analysis
Background: Acute ischaemic stroke (AIS) remains a leading cause of death and disability. This exploratory study integrated transcriptomic and metabolomic analyses to identify candidate hub genes and metabolites associated with AIS and to provide preliminary insights into its molecular mechanisms and potential therapeutic targets. Methods: Metabolomic sequencing data were analyzed using orthogonal partial least squares discriminant analysis (OPLS-DA), together with multivariate and univariate analyses, to identify differentially expressed metabolites (DEMs). Differential gene expression analysis was performed using the GSE16561 dataset, and key genes were screened through protein–protein interaction network analysis, machine learning, expression validation, and diagnostic evaluation. Co-enrichment analysis of key genes and DEMs was then conducted, followed by immune infiltration analysis, molecular network construction, drug prediction, and RT-qPCR validation. Results: A total of 103 and 51 DEMs were identified in the positive and negative ion modes, respectively, and were mainly enriched in steroid hormone biosynthesis. Five key genes—ITGAM, TLR4, MMP9, STAT3, and TLR2—were identified as significantly dysregulated in AIS and showed good diagnostic performance. RT-qPCR confirmed increased expression of TLR4, MMP9, and TLR2 in AIS, whereas ITGAM and STAT3 showed inverse trends. Joint enrichment analysis indicated that key genes and DEMs were mainly involved in 30 pathways, including the HIF-1 and FoxO signaling pathways. Immune infiltration analysis showed that ITGAM had the strongest negative correlation with memory B cells ( p < 0.01, r = −0.39). In the clinical metabolomics cohort, 10 AIS patients and 10 non-stroke controls were included. AIS patients were 70.0% male (7/10) with a mean age of 65.70 ± 6.48 years, while controls were 60.0% male (6/10) with a mean age of 66.64 ± 7.18 years. Blood samples were obtained within 24 h of stroke onset. Stroke subtypes included large artery atherosclerosis ( n = 3), cardioembolism ( n = 5), and small artery occlusion ( n = 2). None of the patients underwent intravenous thrombolysis or mechanical thrombectomy, all received standard medical treatment for AIS. In addition, 28 candidate drugs, including paregoric and celecoxib, were predicted. Conclusion: This exploratory study identified candidate hub genes and metabolites associated with AIS and highlighted their related pathways, immune features, molecular networks, and candidate drugs. These findings provide preliminary insights into the molecular basis and potential therapeutic targets of AIS.
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1767562
Open AccessIdentification of key genes and metabolites in acute ischemic stroke via integrated transcriptomic and metabolomic analysis
Background: Acute ischaemic stroke (AIS) remains a leading cause of death and disability. This exploratory study integrated transcriptomic and metabolomic analyses to identify candidate hub genes and metabolites associated with AIS and to provide preliminary insights into its molecular mechanisms and potential therapeutic targets. Methods: Metabolomic sequencing data were analyzed using orthogonal partial least squares discriminant analysis (OPLS-DA), together with multivariate and univariate analyses, to identify differentially expressed metabolites (DEMs). Differential gene expression analysis was performed using the GSE16561 dataset, and key genes were screened through protein–protein interaction network analysis, machine learning, expression validation, and diagnostic evaluation. Co-enrichment analysis of key genes and DEMs was then conducted, followed by immune infiltration analysis, molecular network construction, drug prediction, and RT-qPCR validation. Results: A total of 103 and 51 DEMs were identified in the positive and negative ion modes, respectively, and were mainly enriched in steroid hormone biosynthesis. Five key genes—ITGAM, TLR4, MMP9, STAT3, and TLR2—were identified as significantly dysregulated in AIS and showed good diagnostic performance. RT-qPCR confirmed increased expression of TLR4, MMP9, and TLR2 in AIS, whereas ITGAM and STAT3 showed inverse trends. Joint enrichment analysis indicated that key genes and DEMs were mainly involved in 30 pathways, including the HIF-1 and FoxO signaling pathways. Immune infiltration analysis showed that ITGAM had the strongest negative correlation with memory B cells ( p < 0.01, r = −0.39). In the clinical metabolomics cohort, 10 AIS patients and 10 non-stroke controls were included. AIS patients were 70.0% male (7/10) with a mean age of 65.70 ± 6.48 years, while controls were 60.0% male (6/10) with a mean age of 66.64 ± 7.18 years. Blood samples were obtained within 24 h of stroke onset. Stroke subtypes included large artery atherosclerosis ( n = 3), cardioembolism ( n = 5), and small artery occlusion ( n = 2). None of the patients underwent intravenous thrombolysis or mechanical thrombectomy, all received standard medical treatment for AIS. In addition, 28 candidate drugs, including paregoric and celecoxib, were predicted. Conclusion: This exploratory study identified candidate hub genes and metabolites associated with AIS and highlighted their related pathways, immune features, molecular networks, and candidate drugs. These findings provide preliminary insights into the molecular basis and potential therapeutic targets of AIS.
- Open Access
- 24 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2)
Waking up to the truth: Associations between sleep disorders and multidomain functional outcomes in Alzheimer's disease
INTRODUCTION: Sleep disorders are common in older adults and have been increasingly linked to cognitive dysfunction in Alzheimer's disease (AD); however, their associations with functional outcomes and underlying pathways remain insufficiently characterized. METHODS: We performed a cross‐sectional analysis of 10,823 participants from the National Alzheimer's Coordinating Center database, examining associations between sleep disorders and instrumental activities of daily living (IADL) using regression, structural equation modeling (SEM), and mediation analyses. RESULTS: Sleep disorders were significantly associated with greater cognitive impairment and poorer IADL performance among individuals with AD. Mediation analysis indicated that cognitive impairment accounted for ≈62% of the association between sleep disorders and IADL difficulties, suggesting a substantial indirect association through cognitive function. DISCUSSION: Sleep disorders are strongly associated with cognitive impairment and functional limitations in AD. These findings highlight the potential clinical value of screening and managing sleep problems as part of comprehensive care strategies.
- 24 February 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (2)
Open AccessWaking up to the truth: Associations between sleep disorders and multidomain functional outcomes in Alzheimer's disease
INTRODUCTION: Sleep disorders are common in older adults and have been increasingly linked to cognitive dysfunction in Alzheimer's disease (AD); however, their associations with functional outcomes and underlying pathways remain insufficiently characterized. METHODS: We performed a cross‐sectional analysis of 10,823 participants from the National Alzheimer's Coordinating Center database, examining associations between sleep disorders and instrumental activities of daily living (IADL) using regression, structural equation modeling (SEM), and mediation analyses. RESULTS: Sleep disorders were significantly associated with greater cognitive impairment and poorer IADL performance among individuals with AD. Mediation analysis indicated that cognitive impairment accounted for ≈62% of the association between sleep disorders and IADL difficulties, suggesting a substantial indirect association through cognitive function. DISCUSSION: Sleep disorders are strongly associated with cognitive impairment and functional limitations in AD. These findings highlight the potential clinical value of screening and managing sleep problems as part of comprehensive care strategies.
- Open Access
- 1 February 2026
- Vol. 22 (2) , e71200
Waking up to the truth: Associations between sleep disorders and multidomain functional outcomes in Alzheimer's disease.
Sleep disorders are common in older adults and have been increasingly linked to cognitive dysfunction in Alzheimer's disease (AD); however, their associations with functional outcomes and underlying pathways remain insufficiently characterized. We performed a cross-sectional analysis of 10,823 participants from the National Alzheimer's Coordinating Center database, examining associations between sleep disorders and instrumental activities of daily living (IADL) using regression, structural equation modeling (SEM), and mediation analyses. Sleep disorders were significantly associated with greater cognitive impairment and poorer IADL performance among individuals with AD. Mediation analysis indicated that cognitive impairment accounted for ≈62% of the association between sleep disorders and IADL difficulties, suggesting a substantial indirect association through cognitive function. Sleep disorders are strongly associated with cognitive impairment and functional limitations in AD. These findings highlight the potential clinical value of screening and managing sleep problems as part of comprehensive care strategies.
- 1 February 2026
- Vol. 22 (2) , e71200
Open AccessWaking up to the truth: Associations between sleep disorders and multidomain functional outcomes in Alzheimer's disease.
Sleep disorders are common in older adults and have been increasingly linked to cognitive dysfunction in Alzheimer's disease (AD); however, their associations with functional outcomes and underlying pathways remain insufficiently characterized. We performed a cross-sectional analysis of 10,823 participants from the National Alzheimer's Coordinating Center database, examining associations between sleep disorders and instrumental activities of daily living (IADL) using regression, structural equation modeling (SEM), and mediation analyses. Sleep disorders were significantly associated with greater cognitive impairment and poorer IADL performance among individuals with AD. Mediation analysis indicated that cognitive impairment accounted for ≈62% of the association between sleep disorders and IADL difficulties, suggesting a substantial indirect association through cognitive function. Sleep disorders are strongly associated with cognitive impairment and functional limitations in AD. These findings highlight the potential clinical value of screening and managing sleep problems as part of comprehensive care strategies.